On Friday, Lazard Ltd (NYSE:LAZ)’s shares declined -0.46% to $58.16.
Lazard Ltd (LAZ) has authorized the Fund to declare recently, following a level distribution policy, a monthly distribution of $0.09282 per share on the Fund’s outstanding common stock. The distribution is payable on July 23, 2015 to shareholders of record on July 13, 2015. The ex-dividend date is July 9, 2015.
Lazard Ltd, together with its auxiliaries, operates as a financial advisory and asset administration firm. Its Financial Advisory segment offers various financial advisory services on mergers and acquisitions, and other planned matters, in addition to on restructurings, capital structure, capital raising, and other financial matters.
Arrowhead Research Corp (NASDAQ:ARWR)’s shares dropped -0.70% to $7.13.
Arrowhead Research Corp (ARWR) declared that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection (HBV), has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are predictable shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies.
The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen (HBeAg) negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology comprise Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types.
At the end of Friday’s trade, 21Vianet Group Inc (NASDAQ:VNET)‘s shares dipped -1.44% to $21.25.
21Vianet Group Inc (VNET) declared that in response to the preliminary non-binding proposal dated June 10, 2015 (the “Proposal”) from Mr. Josh Sheng Chen, the Chairman and Chief Executive Officer of the Company, Kingsoft Corporation Limited and Tsinghua Unigroup International Co., Ltd. (collectively, the “Buyer Group”) that the Company’s board of directors (the “Board”) received, the Board has formed a special committee of independent directors (the “Special Committee”) to review and evaluate the Proposal.
The Special Committee is composed of Mr. Yoshihisa Ueno, Mr. Kenneth Chung-Hou Tai and Mr. Steve Zhang, who are independent directors of the Company and are unassociated with the Proposal. Mr. Ueno will be the chairman of the Special Committee. The Board also anticipates that the Special Committee will retain independent advisors, counting independent financial and legal advisors, to assist it in this process.
21Vianet Group, Inc. provides carrier-neutral Internet data center services to Internet companies, government entities, blue-chip enterprises, and small- to mid-sized enterprises in the People’s Republic of China. It offers hosting and related services to house servers and networking equipment in its data centers, and connects them through a data transmission network; and other hosting related value-added services.
Commscope Holding Company Inc (NASDAQ:COMM), ended its Friday’s trading session with -0.28% loss, and closed at $31.79.
CommScope Holding Company, Inc. (COMM) has declared the sale of 20,000,000 shares of its common stock on an underwritten basis by an associate of The Carlyle Group. In addition, the underwriter will have an option to purchase up to 3,000,000 additional shares from Carlyle. CommScope will not receive any of the proceeds from the offering of shares by Carlyle. Closing of the offering is predictable to occur on or about June 16, 2015, subject to customary closing conditions.
J.P. Morgan Securities LLC is acting as the sole underwriter for the offering. J.P. Morgan Securities LLC proposes to offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the Nasdaq Global Select Market, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.
Following the offering, Carlyle will continue to beneficially own 61,216,970 shares, or about 32%, of CommScope’s outstanding common stock after giving effect to the offering (or 58,216,970 shares, or about 31%, if the underwriter fully exercises its option to purchase additional shares). The sale of the shares of common stock contemplated hereby will trigger the obligation under the Amended and Restated Stockholders Agreement for three Carlyle designees to CommScope’s Board of Directors to resign upon closing of the offering. In addition, going forward, Carlyle will only be afforded the right to designate six directors rather than nine. However, CommScope’s Board of Directors anticipates that it will waive the obligation that three Carlyle designees right away resign and allow such directors to continue to serve their remaining terms.
CommScope Holding Company, Inc., together with its auxiliaries, provides connectivity and infrastructure solutions for wireless, business enterprise, and residential broadband networks worldwide. The company operates through three segments: Wireless, Enterprise, and Broadband.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
